Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX)
|
Add to portfolio |
|
|
|
| Price: |
$0.02
| | Metrics |
| OS: |
14.5
|
M
| |
|
|
| Market cap: |
$306.1
|
k
| |
-40
|
% ROIC
|
|
Net debt:
|
$147
|
M
| |
|
|
|
EV:
|
$147
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($89.4)
|
M
| |
|
|
|
EBIT
|
($48.4)
|
M
| |
|
|
| EPS |
$3.28
| |
0.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 146.1 | 140.9 | 175.9 | 121.7 | 84.9 | 61.3 | 60.6 | 33.2 |
| Revenue growth | 3.7% | -19.9% | 44.4% | 43.4% | 38.4% | 1.2% | 82.4% | 19.0% |
| Cost of goods sold | 44.6 | 43.3 | 51.4 | 48.0 | 43.9 | 23.4 | 20.9 | 5.4 |
| Gross profit | 101.4 | 97.5 | 124.4 | 73.8 | 41.0 | 37.9 | 39.7 | 27.8 |
| Gross margin | 69.4% | 69.2% | 70.8% | 60.6% | 48.3% | 61.9% | 65.5% | 83.6% |
| Selling, general and administrative | 157.9 | 237.9 | 24.4 | 104.0 | 19.4 | 35.5 | 22.2 | 15.2 |
| Research and development | | | | | | 0.7 | 0.9 | 1.0 |
| EBITA | 16.5 | -54.8 | 16.3 | 2.5 | -27.1 | 1.7 | 15.8 | 10.8 |
| EBITA margin | 11.3% | -38.9% | 9.3% | 2.0% | -32.0% | 2.8% | 26.1% | 32.5% |
| Amortization of intangibles | 73.0 | 85.5 | 94.3 | 32.7 | 7.3 | 2.9 | 2.2 | 1.2 |
| EBIT | -56.5 | -140.3 | -78.0 | -30.2 | -34.4 | -1.2 | 13.6 | 9.6 |
| EBIT margin | -38.7% | -99.6% | -44.4% | -24.8% | -40.6% | -2.0% | 22.4% | 29.0% |
| Pre-tax income | -76.8 | -169.2 | -141.3 | -49.0 | -46.4 | -1.8 | 12.9 | 12.3 |
| Income taxes | 0.4 | 0.4 | 7.1 | -13.7 | -20.8 | -0.4 | 4.6 | 1.5 |
| Tax rate | | | | 28.0% | 44.7% | 21.0% | 35.5% | 12.1% |
| Net income | 0.0 | 0.0 | 0.0 | -35.3 | -28.6 | -1.4 | 8.3 | 9.3 |
| Net margin | 0.0% | 0.0% | 0.0% | -29.0% | -33.7% | -2.3% | 13.8% | 28.0% |
| |
| Diluted EPS | $0.00 | $0.00 | $0.00 | ($0.93) | ($0.79) | ($0.05) | $0.34 | $0.46 |
| Shares outstanding (diluted) | 10.7 | 7.8 | 5.3 | 37.9 | 36.4 | 28.1 | 24.5 | 23.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|